mogrol : A tetracyclic triterpenoid that is cucurbitadienol in which the side-chain double bond (position 24-25) has undergone formal oxidation to introduce hydroxy groups at positions 24 and 25 (the 24R stereoisomer). It is a biometabolite of mogrosides found in Siraitia grosvenorii. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Siraitia | genus | [no description available] | Cucurbitaceae | The gourd plant family of the order Violales, subclass Dilleniidae, class Magnoliopsida. It is sometimes placed in its own order, Cucurbitales. 'Melon' generally refers to CUCUMIS; CITRULLUS; or MOMORDICA.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 14525327 |
| CHEMBL ID | 1829226 |
| CHEBI ID | 138974 |
| SCHEMBL ID | 12857257 |
| Synonym |
|---|
| CHEBI:138974 |
| (1s,4r,9beta,11alpha,24r)-9,10,14-trimethyl-4,9-cyclo-9,10-secocholest-5-ene-1,11,24,25-tetrol |
| (24r)-cucurbit-5-ene-3beta,11alpha,24,25-tetraol |
| mogrol |
| CHEMBL1829226 |
| 88930-15-8 |
| SCHEMBL12857257 |
| AC-34411 |
| HY-N2312 |
| CS-6010 |
| JLYBBRAAICDTIS-AYEHCKLZSA-N |
| AKOS030631735 |
| (23r)-cucurbit-5-ene-3beta,11alpha,23,25-tetraol |
| (10alpha,24r)-9beta-methyl-19-norlanosta-5-ene-3beta,11alpha,24,25-tetrol |
| MS-28848 |
| (3s,8s,9r,10r,11r,13r,14s,17r)-17-[(2r,5r)-5,6-dihydroxy-6-methylheptan-2-yl]-4,4,9,13,14-pentamethyl-2,3,7,8,10,11,12,15,16,17-decahydro-1h-cyclopenta[a]phenanthrene-3,11-diol |
| bdbm50537682 |
| Role | Description |
|---|---|
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| tetracyclic triterpenoid | Any triterpenoid consisting of a tetracyclic skeleton. |
| hydroxy seco-steroid | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| 5'-AMP-activated protein kinase subunit gamma-1 | Homo sapiens (human) | EC50 (µMol) | 3.0000 | 0.0168 | 1.2488 | 5.9000 | AID1646329 |
| 5'-AMP-activated protein kinase catalytic subunit alpha-2 | Homo sapiens (human) | EC50 (µMol) | 3.0000 | 0.0168 | 1.3463 | 5.9000 | AID1646329 |
| 5'-AMP-activated protein kinase subunit beta-1 | Homo sapiens (human) | EC50 (µMol) | 3.0000 | 0.0168 | 1.2488 | 5.9000 | AID1646329 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID620412 | Activation of AMPK in human HepG2 cells assessed as increase in AMPK phosphorylation at 1 to 20 uM after 30 mins by Western blotting | 2011 | Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19 | Potential AMPK activators of cucurbitane triterpenoids from Siraitia grosvenorii Swingle. |
| AID1763704 | Antiproliferative activity against human A549 cells assessed as reduction in cell growth by CCK8 assay | |||
| AID1763702 | Antiproliferative activity against human A549 cells assessed as reduction in cell growth at 30 uM by CCK8 assay relative to control | |||
| AID1646329 | Allosteric activation of AMPK alpha2/beta1/gamma1 in human HepG2 cells by scintillation proximity assay | 2020 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2 | Design, synthesis and biological evaluation of mogrol derivatives as a novel class of AMPKα2β1γ1 activators. |
| AID1851633 | Antiproliferative activity against human A549 cells | 2022 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 74 | Design and synthesis of mogrol derivatives modified on a ring with anti-inflammatory and anti-proliferative activities. |
| AID1851636 | Antiproliferative activity against human NCI-H1975 cells | 2022 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 74 | Design and synthesis of mogrol derivatives modified on a ring with anti-inflammatory and anti-proliferative activities. |
| AID1763705 | Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell growth by CCK8 assay | |||
| AID1851625 | Inhibition of LPS-induced NO production in mouse RAW264.7 cells at 10 uM relative to control | 2022 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 74 | Design and synthesis of mogrol derivatives modified on a ring with anti-inflammatory and anti-proliferative activities. |
| AID1851635 | Antiproliferative activity against human NCI-H1299 cells | 2022 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 74 | Design and synthesis of mogrol derivatives modified on a ring with anti-inflammatory and anti-proliferative activities. |
| AID1851634 | Antiproliferative activity against human NCI-H460 cells | 2022 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 74 | Design and synthesis of mogrol derivatives modified on a ring with anti-inflammatory and anti-proliferative activities. |
| AID1763703 | Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell growth at 30 uM by CCK8 assay relative to control | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 6 (85.71) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (33.99) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||